Thursday, October 15, 2020 10:07:43 PM
Once the human trial starts in a few short weeks in Q4 there is NOTHING else needed to bring B-CV19 to commerciality as IMO the P2 will be expanded into a P3 and the results will be such that even "dark pool" players in the FDA won't be able to hold it back any longer. I think CV19 is too big and too sensitive for any governmental body to try and hold it up for political or payola reasons. Distribution will take care of itself in it being sold directly to countries and major healthcare systems worldwide.
IPIX already has the money for the CV human trial or govt will fund it.
IPIX also has the money for the pill Ulcerative Colitis P2 trial and the P3 B-OM trial which IPIX will have to fund. Money is not the issue right now. Getting these two indications further down the line ramps up their values tremendously.
Now if some BP wanted to provide some major funding to get in on the COPD/Asthma, Dermatology, other coronavirus indications to include the flu, HIV, Herpes, etc maybe IPIX would want to talk. But within a few months IPIX should have MAJOR fund influx from a B-IBD deal and possibly funds from OM deal and certainly grant monies for further full range investigations of Brilacidin which will cost them nothing and amaze the medical world as to defensin mimetics and their wonderful properties. This is when some BP may offer IPIX a staggering sum for the Brilacidin platform.
But IPIX is now in the drivers seat. Especially when the RBL results and the peer review article data becomes widely known.
Too many still willing to settle for pennies when we are sitting on a major gold mine IMO.
I cannot envision IPIX not being LARGE funding for all Brilacidin testing, to include human trials. Once the publicity gag is removed and the media gets hold of B's test results, it would be hard for the government to say how they invested BILLIONS in Remsdes.... which is a POGarbage and yet they have only given IPIX XX million? Payola can only go so far.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM